阳光诺和（688621）收购实控人利虔旗下的江苏朗研生命科技控股有限公司（以下简称"朗研生命"） 100%股权的事项最终还是未能成行。1月28日，阳光诺和宣布终止重大资产重组，而这也是阳光诺和自 2022年以来第二次收购朗研生命告败。与前次交易终止的原因相同，此次终止并购同样是由于市场环境 变化。值得一提的是，此次重组获上交所受理后，上交所向阳光诺和下发审核问询函，要求公司于一个 月内进行回复，阳光诺和已申请一次延期。随着回复时间临近，阳光诺和并未回复问询函，而是选择终 止本次交易。 1月28日，阳光诺和发布公告称，公司决定终止发行股份及可转换公司债券购买资产并募集配套资金暨 关联交易事项并撤回申请文件，同时授权公司管理层全权办理本次交易终止的各项事宜。 据了解，阳光诺和原拟通过发行股份及可转换公司债券方式购买朗研生命100%股权，并向不超过35名 特定投资者发行股份募集配套资金。此次重组始于2025年4月，并于同年5月中旬披露重组预案。2025年 11月，阳光诺和上述重组事项获上交所受理。 资料显示，朗研生命主要从事高端化学药品制剂及原料药的研发、生产、销售，并对外提供药品生产服 务。朗研生命致力于成为专业 ...

Group 1 - The core point of the article is that Yangguang Nuohuo (688621) plans to acquire 100% equity of Jiangsu Langyan Life Science Technology Co., Ltd. for a transaction price of 1.2 billion yuan through the issuance of shares and convertible bonds [1] - The acquisition will enhance the company's pharmaceutical industrial segment, achieving a "CRO + pharmaceutical industry" layout [1] - The company intends to raise supporting funds by issuing shares to no more than 35 specific investors [1]

Group 1: Company Performance - Changyuan Donggu achieved a net profit of 230 million in 2024, a year-on-year increase of 5%[1] - In Q4 2024, the company reported a net profit of 75 million, a significant year-on-year increase of 292%[1] - For Q1 2025, the net profit continued to grow, reaching 78 million, up 66% year-on-year[1] Group 2: Market Overview - The ChiNext Index rose by 1.38% last week, while the Shanghai Composite Index increased by 0.76%[3] - The small-cap index experienced a slight decline of 0.02% during the same period[3] - The overall net increase and decrease in shares amounted to -5.188 billion, with 46 companies increasing and 143 companies decreasing their holdings[32] Group 3: Corporate Actions - One company, Sunshine Nuohuo, announced a merger and acquisition plan last week[18] - Two companies, Tangyuan Electric and Wangli Security, released project-based fundraising plans[19] - Nine companies, including Fengguang Precision and Jidong Cement, announced equity incentive plans[21]

Core Viewpoint - Sunshine Nuohong (688621.SH) has resumed trading and announced a plan to acquire 100% equity of Langyan Life from its shareholders through the issuance of shares and convertible bonds, alongside raising matching funds from specific investors [1][2]. Group 1: Transaction Details - The company plans to issue shares at a price not lower than 80% of the average trading price of its stock over the previous 120 trading days, which is set at 34.05 yuan per share [2]. - The issuance of convertible bonds will also be priced at 34.05 yuan per share, with a face value of 100 yuan per bond [2]. - The total amount of matching funds raised will not exceed 100% of the transaction price for the asset purchase, with the number of shares issued not exceeding 30% of the company's total share capital prior to the transaction [3]. Group 2: Financial Information of Langyan Life - As of the end of 2024, Langyan Life has total assets of 1,126.87 million yuan and total liabilities of 403.96 million yuan [5][7]. - The company reported revenues of 465.08 million yuan in 2023 and 431.47 million yuan in 2024, with net profits of 36.17 million yuan and 54.39 million yuan for the respective years [5][9]. - The equity attributable to the parent company increased from 640.54 million yuan in 2023 to 703.10 million yuan in 2024 [7]. Group 3: Company Structure and Control - The transaction is classified as a related party transaction, as Langyan Life is controlled by the company's major shareholder, Li Quan [4]. - The company’s total share capital is 112 million shares, with Li Quan holding 30.90 million shares, representing 27.59% of the total [3]. - The transaction is not expected to change the control of the company [4].

Core Viewpoint - The company plans to acquire 100% equity of Jiangsu Langyan Life Technology Holdings Co., Ltd. through the issuance of shares and convertible bonds, which aligns with the regulations of the Shanghai Stock Exchange's Sci-Tech Innovation Board [2][4] Group 1: Industry Alignment - The target company operates in the "C27 Pharmaceutical Manufacturing" sector, which is upstream and downstream related to the company's business, thus meeting the Sci-Tech Innovation Board's positioning requirements [2][3] - According to the National Bureau of Statistics, the target company's industry falls under the "4.1.2 Chemical Drugs and Raw Materials Manufacturing" category within the "4 Biological Industry," qualifying it as part of the biopharmaceutical field [3] Group 2: Synergy Between Companies - The company specializes in comprehensive preclinical and clinical drug research services (CRO) and has a demand for self-developed products, while the target company focuses on high-end chemical drugs and raw materials, having established a mature pharmaceutical production system [3] - The acquisition will enable the company to leverage the target's complete pharmaceutical production capabilities, enhancing research efficiency and reducing costs, while optimizing production processes and ensuring quality [3] - This transaction is expected to maximize the commercial value of the company's proprietary products and create new profit growth points by combining the research advantages of the company with the production and sales strengths of the target [3]

Core Viewpoint - The company plans to acquire 100% equity of Jiangsu Langyan Life Science Technology Co., Ltd. through the issuance of shares and convertible bonds, which aligns with relevant regulations and policies [1][2][7]. Compliance with Regulations - The transaction complies with national industrial policies and relevant laws regarding environmental protection, land management, anti-monopoly, foreign investment, and outbound investment [1][2]. - The transaction does not require prior approval from the Ministry of Commerce as it does not meet the concentration declaration standards [2]. - The transaction will not affect the company's compliance with stock listing conditions, as the public shareholding ratio will remain above 25% post-transaction [2][3]. Asset Valuation and Legality - The asset pricing is fair and does not harm the company's or shareholders' legal rights, with an independent evaluation process in place [3][4]. - The ownership of the assets is clear, and there are no legal obstacles to the transfer of ownership [4][5][10]. Business Synergy and Growth Potential - The acquisition is expected to enhance the company's operational capabilities by leveraging its R&D strengths alongside Langyan's production and sales advantages, creating new profit growth points [5][11]. - The transaction will expand the company's business into the pharmaceutical industrial sector, establishing a "CRO + pharmaceutical industry" layout that is anticipated to improve profitability and risk resistance [5][7]. Independence and Governance - The company maintains independence from its controlling shareholders in terms of business, assets, finance, personnel, and institutions, complying with relevant regulations [6][8]. - The company has a sound corporate governance structure, ensuring compliance with laws and regulations post-transaction [6][7]. Financial Health and Compliance - The company has received a standard unqualified audit report for the last fiscal year, indicating no issues with financial reporting [8][9]. - The transaction will reduce related party transactions and avoid competition with the controlling shareholder's other enterprises, enhancing the company's independence [7][8].